Effectiveness and tolerability of pegylated interferon α-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: From clinical trials to clinical practice

Romanian Journal of Gastroenterology

Volumn 14, Issue 2, 2005, Pages 109-115

  Gheorghe, Liana ^a   Grigorescu, Mircea ^b   Iacob, Speranta ^a   Damian, Dana ^b   Gheorghe, Cristian ^a   Iacob, Rǎzvan ^a   Simionov, Iulia ^a   Vǎdan, Roxana ^a   Pârvulescu, Iuliana ^a   Bǎncilǎ, Ion ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chronic hepatitis C; Pegylated interferon plus ribavirin therapy; Side effects; Virological response

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CHILL; CLINICAL PRACTICE; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FATTY LIVER; FEMALE; FEVER; FIBROSIS; HEADACHE; HEPATITIS C; HUMAN; HUMAN TISSUE; INFECTION COMPLICATION; INFLAMMATION; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MYALGIA; NAUSEA AND VOMITING; PIACENZIAN; PRURITUS; RASH; SIDE EFFECT; STOMATITIS; TASTE DISORDER; VISUAL DISORDER; WEIGHT REDUCTION; XEROSTOMIA;

EID: 21644455372     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Di Bisceglie A, Hoofnagle J. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-S127
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al; PEGASYS International Study Group. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
5. McHutchinson JG, Manns M, Patel K, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069
6. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol 2004; 40: 993-999
7. Diago M, Hassanein T, Rodes J, Ackrill A, Sedarati F. Optimizing virologic response in hepatitis C virus genotype 4 with peginterferon-alpha 2a and ribavirin. Ann Intern Med 2004; 140: 72-73
8. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-681
9. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244
10. Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get here? Ann Intern Med 2002; 137: 10-16
11. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8: 377-383
12. Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok AS. Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naïve chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004; 2: 425-431
13. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435
14. Grigorescu M, Radu C, Pascu O, et al. Etiological profile of chronic hepatitis and liver cirrhosis in Romania - a multicentre study. Rom J Gastroenterol 2001; 10: 199-204
15. Grigorescu, M, Voiosu, R, Stanciu C, et al. Consensus Conference of the Romanian Society of Gastroenterology and Hepatology-Treatment of chronic hepatitis. Rom J Gastroenterol 2002; 11: 237-245
16. Carithers RL Jr, Emersson SS. Therapy of hepatitis C: meta-analysis of interferon alpha-2b trials. Hepatology 1997; 26: S83-S88
17. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
18. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432
19. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881
20. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-1127
21. Johnson TC, Vaseer S, Iqbal S, Clam DJ, Bodenheimer HC, Min AD. The effectiveness of pegylated-interferon and ribavirin combination therapy for chronic hepatitis C in an urban clinic setting compared to pivotal clinical trials. Gastroenterology 2004; 126 (Suppl 2): A-724 (M1242)
22. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-496
23. Spence JD, Hurley TC, Spence J. Actual practice in hypertension: implications for persistence with and effectiveness of therapy. Curr Hypertension Rep 2001; 3: 481-487
24. Gladstone DJ, Black SE. Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. Can Med Assoc J 2001; 165: 311-317
25. Parker G, Roy K, Wilhelm K, Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J Clin Psychiatry 2001; 62: 117-125
26. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138: 187-190